M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 4.84 USD -0.82% Market Closed
Market Cap: 166.4m USD

Myomo Inc
Investor Relations

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

Show more
Loading

Earnings Calls

2024 Q4
Mar 11, 2025
Show Transcript
Previous
Next
Core Molding Technologies navigates challenges while preparing for future growth.
2024 Q4
Mar 11, 2025

Core Molding reported a significant decline in 2024 sales, down 15.5% to $302.4 million, primarily due to a cyclical downturn in the truck market. However, gross margins held steady at 17.6%, and EBITDA was $33.8 million. The company anticipates 2025 revenues to be flat but expects a 5-10% decline in the first half due to the ongoing Volvo transition, which will reduce revenues by approximately $30 million. Despite this, they project tooling sales to reach between $30-40 million, driven by new business wins. A restructuring plan should yield $2.6 million in annual savings, positioning them for a rebound in 2026.

Show Full Analysis

Management

Mr. Paul R. Gudonis
Chairman, President & CEO
No Bio Available
Mr. David A. Henry
Chief Financial Officer
No Bio Available
Dr. Harry Kovelman M.D.
Chief Medical Officer
No Bio Available
Colin Anderson
Global Director of Operations
No Bio Available
Mr. Joseph Chicoskie
Director of Marketing
No Bio Available
Ms. Galina Shtivelman
Senior Director of Human Resources
No Bio Available
Mr. Micah J. Mitchell
Chief Commercial Officer
No Bio Available

Contacts

Address
MASSACHUSETTS
Boston
137 Portland Street, 4th Floor
Contacts
+16179969058
myomo.com